Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,652 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J, Mahlangu JN, Kim B, et al. · N Engl J Med · 2017Clinical Trial, Phase III, Multicenter Study
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J, Oldenburg J, Paz-Priel I, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Comparative Study
- Auto-hypnosis in haemophilia.
LaBaw WL · Haematologia (Budap) · 1975Clinical Trial, Controlled Clinical Trial
- Gene therapy for haemophilia.
Sharma A, Easow Mathew M, Sriganesh V, et al. · Cochrane Database Syst Rev · 2020Research Support, Non-U.S. Gov't, Systematic Review
- Exercise for haemophilia.
Strike K, Mulder K, Michael R · Cochrane Database Syst Rev · 2016Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G, Srivastava A, Kavakli K, et al. · Lancet · 2023Randomized Controlled Trial, Multicenter Study
- Gene therapy for haemophilia.
Sharma A, Easow Mathew M, Sriganesh V, et al. · Cochrane Database Syst Rev · 2016Research Support, Non-U.S. Gov't, Systematic Review
- Gene therapy for haemophilia.
Sharma A, Easow Mathew M, Sriganesh V, et al. · Cochrane Database Syst Rev · 2014Research Support, Non-U.S. Gov't, Systematic Review
- A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
Mahlangu JN, Lamas JL, Morales JC, et al. · Br J Haematol · 2023Clinical Trial, Phase II, Clinical Trial, Phase I
- Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
Chowdary P, Angchaisuksiri P, Apte S, et al. · Lancet Haematol · 2024Multicenter Study, Randomized Controlled Trial
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, et al. · Lancet Haematol · 2019Clinical Trial, Phase III, Multicenter Study
- Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.
Mahlangu J, Boban A, Bruzelius M, et al. · Blood Adv · 2026Clinical Trial, Phase III, Randomized Controlled Trial
- Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.
Mancuso ME, Chan AKC, Shanmukhaiah C, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Hypertension in haemophilia: A meta-analysis.
Ter-Zakarian A, Al Banaa K, Barnes R, et al. · Haemophilia · 2023Meta-Analysis, Letter
- FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.
Lentz SR, Chowdary P, Gil L, et al. · J Thromb Haemost · 2024Clinical Trial, Phase II, Randomized Controlled Trial
- Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Srivastava A, Rangarajan S, Kavakli K, et al. · Lancet Haematol · 2023Randomized Controlled Trial, Multicenter Study
- Surgery for chronic arthropathy in people with haemophilia.
Chin B, Wee I, Syn NL, et al. · Cochrane Database Syst Rev · 2022Research Support, Non-U.S. Gov't, Systematic Review
- [Dental management of patients with haemophilia].
Sipos K · Orv Hetil · 2022Systematic Review
- Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis.
Deshpande SR, Joseph K, Tong J, et al. · Blood Adv · 2024Systematic Review, Meta-Analysis
- Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
Schmitt C, Mancuso ME, Chang T, et al. · Haemophilia · 2023Clinical Trial, Phase III
- Rituximab for eradicating inhibitors in people with acquired haemophilia A.
Remmington T, Smith S · Cochrane Database Syst Rev · 2021Research Support, Non-U.S. Gov't, Systematic Review
- Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
Pasi KJ, Rangarajan S, Georgiev P, et al. · N Engl J Med · 2017Clinical Trial, Phase I, Multicenter Study
- Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis.
Kraemmer D, Königsbrügge O, Moik F, et al. · J Thromb Haemost · 2023Meta-Analysis, Systematic Review
- Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS, Visuddho V, Witarto AP, et al. · F1000Res · 2021Meta-Analysis, Systematic Review
- Central venous access devices in haemophilia.
Valentino LA, Ewenstein B, Navickis RJ, et al. · Haemophilia · 2004Meta-Analysis, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.